Rezolute (RZLT) Debt Ratio (2011 - 2021)
Rezolute recorded quarterly Debt Ratio of 0.05 in Q1 2021, up 385291.76% quarter-over-quarter from 0.0 in Q4 2017.
Rezolute's Debt Ratio history runs 7 years deep, the most recent figure standing at 0.05 for Q1 2021.
- In Q1 2021, Debt Ratio changed N/A year-over-year to 0.05; the TTM figure through Mar 2021 stood at 0.05 (changed N/A YoY), while the FY2017 annual figure was 0.0, down 94.95% from the prior year.
- Debt Ratio came in at 0.05 for Q1 2021 at Rezolute, up from 0.0 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.05 in Q1 2021 to a low of 0.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 0.05 |
| Dec 31, 2017 | 0.00 |
| Sep 30, 2017 | 0.00 |
| Jun 30, 2017 | 0.00 |
| Mar 31, 2017 | 0.00 |
| Dec 31, 2016 | 0.00 |
| Sep 30, 2016 | 0.00 |
| Jun 30, 2016 | 0.00 |
| Mar 31, 2016 | 0.00 |
| Dec 31, 2015 | 0.00 |
| Sep 30, 2015 | 0.00 |
| Jun 30, 2015 | 0.00 |
| Dec 31, 2014 | 0.10 |
| Sep 30, 2014 | 0.06 |
| Jun 30, 2014 | 0.00 |
| Mar 31, 2014 | 0.18 |
| Dec 31, 2013 | 0.50 |
| Sep 30, 2013 | 1.10 |
| Jun 30, 2013 | 0.14 |
| Mar 31, 2013 | 0.33 |
| Dec 31, 2011 | 0.00 |